3.0.0 1396 2019-11-15T21:18:26Z 2019-11-15T21:18:26Z House H HR 2005-03-17 109 hsif00 Energy and Commerce Committee House Standing hsif14 Health Subcommittee Referred to 2005-03-22T22:09:45Z Referred to 2005-03-17T15:06:10Z Tim Fagan's Law 109 2345 HR 2005-05-23 Referred to the Subcommittee on Health. Related bill CRS 2005-03-22 hsif14 Health Subcommittee 1 House committee actions Referred to the Subcommittee on Health. Committee 2005-03-17 Referred to the House Committee on Energy and Commerce. IntroReferral H11100 2 House floor actions hsif00 Energy and Commerce Committee 2005-03-17 Introduced in House IntroReferral Intro-H 9 Library of Congress 2005-03-17 Introduced in House IntroReferral 1000 9 Library of Congress I000057 Rep. Israel, Steve [D-NY-2] STEVE ISRAEL D NY 2 N Health Administrative remedies Commerce Communication in medicine Consumer protection Crime and Law Enforcement Criminal justice information Defective products Department of Health and Human Services Drug adulteration Drug industry Drugs Fines (Penalties) Food and Drug Administration (FDA) Government Operations and Politics Government paperwork Governmental investigations Informers Intellectual property Labeling Law Medical personnel Product counterfeiting Health 00 2005-03-17 Introduced in House 2005-04-25T20:34:00Z Counterfeit Drug Enforcement Act - Amends the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services, upon a finding of reasonable probability that a drug intended for human use would cause serious health consequences or death, to issue an order requiring the appropriate person (including the manufacturers, importers, distributors, or retailers of the drug) to: (1) cease distribution of the drug; (2) notify health professionals of the order and instruct such professionals to cease administering or prescribing the drug; and (3) amend the order to include a recall if necessary.

Establishes a criminal fine and/or imprisonment for a person who: (1) knowingly causes a prescription drug to be adulterated or misbranded and sells or trades the drug; or (2) purchases or trades for such drug knowing or having reason to know that the drug was knowingly adulterated or misbranded. Requires a manufacturer of a drug to notify the Secretary within 48 hours after first receiving or becoming aware of information that reasonably suggests that such a violation may have occurred.

Increases funding for Food and Drug Administration (FDA) inspections, examinations, and investigations.

]]> Counterfeit Drug Enforcement Act Short Titles as Introduced Counterfeit Drug Enforcement Act Display Title Counterfeit Drug Enforcement Act Official Title as Introduced To amend the Federal Food, Drug, and Cosmetic Act to establish recall authority regarding drugs, to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, and for other purposes. Introduced in House 2005-03-17T05:00:00Z https://www.govinfo.gov/content/pkg/BILLS-109hr1396ih/xml/BILLS-109hr1396ih.xml 2005-03-22 Referred to the Subcommittee on Health. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.